Mineralys Therapeutics (MLYS) Accounts Payables (2022 - 2026)

Mineralys Therapeutics has disclosed Accounts Payables across 5 years of filings, most recently posting $1.1 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.1 million, up 199.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (up 199.2% YoY), and the FY2025 annual result was $2.0 million, up 321.09% from the prior year.
• Accounts Payables came in at $1.1 million for Q1 2026 at Mineralys Therapeutics, down from $2.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.6 million in Q3 2023 to a low of $373000.0 in Q1 2025.
• The 5-year median for Accounts Payables is $2.0 million (2022), against an average of $2.1 million.
• Peak annual rise in Accounts Payables reached 321.09% in 2025, while the deepest fall reached 91.25% in 2025.
• Mineralys Therapeutics' Accounts Payables stood at $1.9 million in 2022, then sank by 68.48% to $601000.0 in 2023, then declined by 20.3% to $479000.0 in 2024, then jumped by 321.09% to $2.0 million in 2025, then plunged by 44.67% to $1.1 million in 2026.
• The last three Accounts Payables figures came in at $1.1 million (Q1 2026), $2.0 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.